Cougar Biotechnology to Present Clinical Data on CB7630 (Abiraterone Acetate) at American Society...
redorbit.com     May 22, 2008            

Posted on: Thursday, 22 May 2008, 09:01 CDT Cougar Biotechnology, Inc. (NASDAQ:CGRB) today announced that data from various Phase I and Phase II clinical trials of Cougar's lead drug candidate CB7630 (abiraterone acetate) will be presented during the 44th Annual Meeting of the American Society of... [read full story]                    


View all news articles about*:
ASCO Biotechnology Body Cancer Cancers Chemotherapy Health Location Male Oncology Pharmaceuticals Prostate Therapy
*Newstin tag cloud displays all featured persons, associated organizations, related topics, regions and companies

View other selected articles:

Vion Pharmaceuticals signs agreement with Hovon for Phase III cancer trial

pharmaceutical-business-review.com     7 hrs ago   6 related          

Vion Pharmaceuticals has signed an agreement with the Dutch-Belgian Cooperative Trial Group for Hematology Oncology to conduct a clinical trial of laromustine with standard remission-induction therapy in patients aged 18-65...                    

comments

Eli Lilly acquires SGX Pharmaceuticals

news-medical.net     10 hrs ago          

Eli Lilly and Company has announced that it has completed the acquisition of SGX Pharmaceuticals, Inc. (Public, NASDAQ:SGXP), a San Diego-based biotechnology company focused on drug discovery and development in the area of...                    

comments

                   

Lilly Announces Completion of SGX Acquisition

redorbit.com     14 hrs ago   6 related          

INDIANAPOLIS, Ind., Aug. 20 /PRNewswire-FirstCall/ -- Eli Lilly and Company today announced that it has completed the acquisition of SGX Pharmaceuticals, Inc. , a San Diego-based biotechnology company focused on drug discovery...                    

comments

PDL Could Get $1.2B from BMS for Two Early Stage Antibodies

tmcnet.com     15 hrs ago   14 related          

710M for Elotuzumab After struggling through a year of shifting business strategies, PDL BioPharma Inc. signed an antibody deal with Bristol-Myers Squibb Co. that could be worth nearly $1.16 billion. The deal calls for New...                    

comments